Almirall Plots M&A Moves Ahead Of Lebrikizumab Approval

Raises €200m For Bolt-Ons Or Licensing

16 Jun 2023

The Spanish group has been fairly quiet on the dealmaking front of late but the proceeds of a significant capital raise have been earmarked to help “swiftly execute inorganic growth opportunities.”

Most of the focus at Almirall SA is on securing EU approval for the closely watched atopic dermatitis drug lebrikizumab but the Spanish drugmaker is also looking to bring in other assets to feed the pipeline.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

18 Apr 2025

• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

Sanofi Licenses Bispecific Candidates From AI-Driven Earendil

17 Apr 2025

• By Joseph Haas

Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.

Finance Watch: Investors Push ESSA Pharma, Elevation Oncology To Wind Down

17 Apr 2025

• By Mandy Jackson

Restructuring Edition: ESSA and Elevation are reviewing strategic alternatives after trial failures, but each has an investor urging them to liquidate. Also, Third Harmonic and Vincerx are winding down, while Keros and Tempest are assessing options, but Opthea and OPM are cutting jobs.